This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Chemical Biology Discussion Group Year-End Symposium 2019

Chemical Biology Discussion Group Year-End Symposium 2019

Wednesday, May 22, 2019, 12:30 PM - 6:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

The New York Academy of Sciences

Chemical Biology Discussion Group

 

The goal of the Academy's Chemical Biology Discussion Group is to enhance interactions among local-area laboratories working in chemical biology and to showcase cutting edge research in chemical biology to the wider community. The program features distinguished keynote speakers Dr Emma Parmee, Merck, and Dr. David Spiegel, Yale University, in addition to short, cutting-edge talks covering a range of topics in chemical biology. A committee of experts selects the short talk presenters from abstract submissions. The meeting concludes with a poster session and networking reception.

Registration

Member
$10
Nonmember Academia, Faculty, etc.
$80
Nonmember Corporate, Other
$95
Nonmember Not for Profit
$80
Nonmember Student, Undergrad, Grad, Fellow
$40
Member Student, Post-Doc, Fellow
$5
Deadline:
0
days
left

Scientific Organizing Committee

Jason Imbriglio
Jason Imbriglio, PhD

Merck

Sara Donnelly
Sara Donnelly, PhD

The New York Academy of Sciences

Sonya Dougal
Sonya Dougal, PhD

The New York Academy of Sciences

Keynote Speakers

Emma R. Parmee
Emma R. Parmee, PhD

Merck

David Spiegel
David Spiegel, MD, PhD

Yale University




Wednesday

May 22, 2019

12:30 PM

Registration and Poster Set-Up

1:00 PM

Welcome and Introduction

Speakers

Sara Donnelly, PhD
The New York Academy of Sciences
Jason Imbriglio, PhD
Merck
1:15 PM

Keynote: Using Small Molecules to Engineer and Explore Human Immunity

Speaker

David Spiegel, PhD
Yale University

Research in the Spiegel Laboratory utilizes techniques and insights from organic chemistry to modulate and/or create immunological function. This talk will describe our lab’s recent efforts in this field, which range from complex molecule synthesis to the creation of novel paradigms in immunotherapy. Specific topics to be discussed will include: (1) investigations into advanced glycation end-products (AGEs) – a class of complex, non-enzymatic post-translational modifications of proteins with effects on immune function; (2) rational design and biological characterization of immunomodulatory small molecules.

2:00 PM

N-terminal Degradation Activates the NLRP1B Inflammasome

Speaker

Ashley J. Chui
Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center
2:15 PM

Design of Selective Chemical Inhibitors using Analysis of Resistance

Speaker

Tommaso Cupido, PhD
The Rockefeller University
2:30 PM

Visualizing Signal Transduction Steps in the Light-Sensing Histidine Kinase EL346

Speaker

Igor Dikiy, PhD
CUNY Advanced Science Research Center
2:45 PM

Networking Coffee Break

3:15 PM

Inhibiting the β-Catenin TCF Interaction in Prostate Cancer with Peptoid-Peptide Macrocycles

Speaker

Jeffrey Schneider
NYU School of Medicine
3:30 PM

Elucidation of the Molecular Interactions of Bacterial Peptidoglycan and NLR Innate Immune Protein

Speaker

Elizabeth A. D'Ambrosio
University of Delaware
3:45 PM

Keynote: The Discovery of Glucagon Receptor Antagonists for Clinical Development

Speaker

Emma Parmee, PhD
Merck

Blood glucose levels are maintained by the balance of glucose production in the liver and glucose uptake in peripheral tissues. An inappropriately high rate of hepatic glucose production (HGP) is the predominant cause of fasting hyperglycemia and a major contributor to the postprandial hyperglycemia characteristic of type 2 diabetes (T2DM). The glucagon receptor is predominantly located in the liver and upon activation stimulates hepatic glycogenolysis and gluconeogenesis. Studies in T2DM patients have demonstrated a causal role for glucagon in promoting excessive HGP. Glucagon receptor antagonists (GRAs) therefore have the potential to reduce HGP and be effective antidiabetic agents. This presentation will describe the discovery and development of novel GRAs which have undergone clinical evaluation for the treatment of T2DM. Importantly, a“bedside-to-bench” translation which was undertaken to elucidate the cause of unanticipated clinical safety signals will also be discussed.

4:30 PM

Poster Session and Networking Reception

Speakers

4:30 PM-5:05 PM
Odd Numbered Posters
5:05 PM-5:40 PM Even Numbered Posters
5:50 PM

F1000Research Outstanding Poster Presentation Awards

Speaker

Jason Imbriglio, PhD
Merck
6:00 PM

Adjourn

Loading...